Approximately 90 healthy volunteers, aged between 18 and 30, will be exposed to SARS-Cov-2 virus in a safe and controlled environment.  The trial will be managed jointly by the U.K. Vaccine Task Force, the Imperial College London, the Royal Free London NHS Foundation Trust, and hVIVO a commercial entity that conducts human challenge model studies.

To date, the UK with a population of 63 million has recorded four million cases of COVID-19 with 120,000 fatalities. As of mid-February, 15 million have been vaccinated with at least one dose of either the Oxford-AstraZeneca or Pfizer vaccines since December 8th 2020.